Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France. Show more
Location: 8, rue de la Croix Jarry, Paris, 75013, France | Website: https://www.cellectis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
259.7M
52 Wk Range
$1.10 - $3.24
Previous Close
$2.59
Open
$2.63
Volume
61,135
Day Range
$2.53 - $2.64
Enterprise Value
158.9M
Cash
59.81M
Avg Qtr Burn
-8.337M
Insider Ownership
3.85%
Institutional Own.
18.89%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
UCART20x22 Details Cancer, Non-Hodgkin lymphoma | Phase 1/2 Data readout | |
UCART22 Details Acute lymphoblastic leukemia, Rare genetic disease, Cancer, B-cell acute lymphoblastic leukemia | Phase 1/2 Data readout | |
UCART123 Details Cancer, Relapsed/refractory acute myeloid leukemia | Phase 1 Data readout | |
UCART19 (anti-CD19) Details Cancer, Multiple myeloma, Acute lymphoblastic leukemia | Failed Discontinued | |
UCARTCS1 Details Cancer, Multiple myeloma, Menkes Disease | Failed Discontinued | |
ALLO-715 Details Cancer, Multiple myeloma | Failed Discontinued | |
ALLO-501 Details Non-Hodgkin lymphoma, Cancer | Failed Discontinued |